Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Update

Key Points

• Plus Therapeutics saw a **310.6% increase** in short interest from September 15 to September 30, rising to **16.71 million shares**.
• The company's stock currently has a **market capitalization of $61.54 million**, with a **P/E ratio of -0.28** and trading at approximately **$0.62 per share**.
• Analysts have varying views on Plus Therapeutics, with price targets ranging from **$3.00 to $21.00**, and an average rating of **"Buy"** from seven research firms.

Plus Therapeutics, Inc. (NASDAQ:PSTV - Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 16,710,000 shares, a growth of 310.6% from the September 15th total of 4,070,000 shares. Based on an average daily trading volume, of 22,400,000 shares, the short-interest ratio is presently 0.7 days. Based on an average daily trading volume, of 22,400,000 shares, the short-interest ratio is presently 0.7 days.

Plus Therapeutics Trading Up 1.0%

Shares of PSTV opened at $0.62 on Friday. The firm's 50-day moving average is $0.56 and its two-hundred day moving average is $0.52. Plus Therapeutics has a twelve month low of $0.16 and a twelve month high of $2.31. The firm has a market capitalization of $61.54 million, a P/E ratio of -0.28 and a beta of 0.81.

Plus Therapeutics (NASDAQ:PSTV - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.08. The business had revenue of $1.39 million during the quarter, compared to analyst estimates of $1.08 million. Analysts predict that Plus Therapeutics will post -2.3 EPS for the current year.

Insider Activity at Plus Therapeutics

In other Plus Therapeutics news, Director Robert P. Lenk bought 110,000 shares of Plus Therapeutics stock in a transaction dated Friday, August 22nd. The stock was acquired at an average cost of $0.49 per share, with a total value of $53,900.00. Following the completion of the acquisition, the director owned 139,327 shares of the company's stock, valued at approximately $68,270.23. This represents a 375.08% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.79% of the company's stock.

Hedge Funds Weigh In On Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. Virtu Financial LLC purchased a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 40,030 shares of the company's stock, valued at approximately $38,000. Virtu Financial LLC owned 0.24% of Plus Therapeutics as of its most recent SEC filing. 3.28% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Maxim Group dropped their price target on shares of Plus Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Monday, August 18th. Ascendiant Capital Markets boosted their price target on shares of Plus Therapeutics from $20.50 to $21.00 and gave the stock a "buy" rating in a research note on Monday, October 6th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Plus Therapeutics in a research note on Wednesday, October 8th. D. Boral Capital reiterated a "buy" rating and set a $5.00 price target on shares of Plus Therapeutics in a research note on Thursday, September 25th. Finally, HC Wainwright dropped their price target on shares of Plus Therapeutics from $5.50 to $3.00 and set a "buy" rating on the stock in a research note on Friday, June 27th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $8.00.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.